The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.42
Bid: 17.42
Ask: 18.08
Change: 0.14 (0.80%)
Spread: 0.66 (3.789%)
Open: 17.42
High: 17.42
Low: 17.42
Prev. Close: 17.61
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Relocation of CEO to the US and Director Dealings

9 May 2013 12:30

RNS Number : 3551E
Nanoco Group PLC
09 May 2013
 



 For immediate release

9 May 2013

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Relocation of CEO to the US and Director Dealings

 

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that its CEO, Michael Edelman, is relocating to the US, where he will lead the Company from Boston, MA.

 

This relocation will allow Nanoco to be close to its key US strategic partners and potential customers. It will also give the Company the opportunity to develop its US investor base.

 

To fund his relocation to the US, Michael Edelman informed the Company on 9 May 2013 that, on 9 May 2013, he sold 1,300,000 ordinary shares in the Company ("Ordinary Shares") at 163 pence per Ordinary Share. His resultant shareholding, not including share options, is 6,988,640 Ordinary Shares, equivalent to 3.3% of the Company's share capital.

 

Michael Edelman, Nanoco's Chief Executive Officer, said: "Nanoco has reached a stage in its development where I am spending an increasing amount of time in the US, particularly since signing our key manufacturing and marketing relationship there. We have strategic relationships, customers, potential customers and investors in the US. By relocating, I will have the opportunity to serve and develop these relationships more effectively.

 

"Nanoco's head office will remain in Manchester, UK, and I will continue to divide my time between Manchester, London, Asia and the US."

 

 

 

 

For further information:

 

Nanoco

+ 44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Colin White, Chief Financial Officer

Canaccord Genuity - Nomad and Joint Broker

+44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Liberum Capital - Joint Broker

+ 44 (0) 20 3100 2000

Simon Atkinson

Richard Bootle

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes for editors:

 

About Nanoco Group plc

 

Nanoco is a world leader in the development and production of cadmium-free quantum dots for use in multiple applications including LCD displays, lighting and solar cells. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and business development offices in the USA, Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKLFBXEFLBBK
Date   Source Headline
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company
16th Jul 20202:15 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSResult of Fund Raise
15th Jul 20205:20 pmRNSPrimaryBid.com Offer
15th Jul 20205:17 pmRNSTrading Update and Proposed Fundraising
14th Jul 20209:55 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSLitigation Funding Agreement
2nd Jul 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
30th Jun 202010:06 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSBlocklisting Six-Monthly Return
5th Jun 20204:41 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.